182 related articles for article (PubMed ID: 36193738)
1. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition.
Momtazi-Borojeni AA; Banach M; Ruscica M; Sahebkar A
Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1199-1208. PubMed ID: 36193738
[TBL] [Abstract][Full Text] [Related]
2. A promising therapy for fatty liver disease: PCSK9 inhibitors.
Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
[TBL] [Abstract][Full Text] [Related]
3. Liver fat accumulation is associated with circulating PCSK9.
Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
[TBL] [Abstract][Full Text] [Related]
4. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
[TBL] [Abstract][Full Text] [Related]
6. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways.
Huang P; Ran J; Zhu W; Dai W; Tang Y; Lian P; Huang X; Li R
FASEB J; 2024 Feb; 38(4):e23464. PubMed ID: 38358343
[TBL] [Abstract][Full Text] [Related]
8. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Emma MR; Giannitrapani L; Cabibi D; Porcasi R; Pantuso G; Augello G; Giglio RV; Re NL; Capitano AR; Montalto G; Soresi M; Cervello M
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158792. PubMed ID: 32777481
[TBL] [Abstract][Full Text] [Related]
9. Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.
Zhu W; Ding C; Huang P; Ran J; Lian P; Tang Y; Dai W; Huang X
Sci Rep; 2022 Apr; 12(1):5639. PubMed ID: 35379885
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
11. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
[TBL] [Abstract][Full Text] [Related]
12. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
13. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Nseir W; Mograbi J; Ghali M
Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
[TBL] [Abstract][Full Text] [Related]
15.
Lebeau PF; Byun JH; Platko K; Al-Hashimi AA; Lhoták Š; MacDonald ME; Mejia-Benitez A; Prat A; Igdoura SA; Trigatti B; Maclean KN; Seidah NG; Austin RC
JHEP Rep; 2019 Dec; 1(6):418-429. PubMed ID: 32039393
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
17. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
19. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
Grewal T; Buechler C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
